[National and regional market penetration rates of generic's high dosage buprenorphine: its evolution from 2006 to 2008, using reimbursed drug database].

Objective: To assess the national market penetration rate (PR) of generic high-dosage buprenorphine (HDB) in 2008 and its evolution since their marketing (2006), and making a point for each dosage and at regional level.

Methods: Retrospective study over data using national and regional health reimbursement database over three years (2006-2008).

Results: In 2008, the generic HDB's national MPR was 31%.